Europe is easing restrictions, closing vaccination centres and seeing declining death rates, but COVID-19 cases are rising, and we must be ready for possible future variants, according to the EU's infectious disease agency director.
US biotech firm Novavax started shipping their Novaxovid COVID-19 vaccines to EU member states on Wednesday (23 February). The first protein-based vaccine available in Europe is expected to raise vaccination rates, but its efficiency against omicron is yet to be determined.
While Europeans are rushing to get their booster before nine months - or even less - have passed since their first jab, fewer than 10% of people in low-income countries have received at least one dose and the much-needed doses seem to be running out of date.
French President Emmanuel Macron proposed pressuring pharmaceutical companies to share their knowledge to fight vaccine shortages worldwide, as an alternative to waiving intellectual property (IP) rights.
The World Health Organization warned countries on Tuesday (30 November) not to impose blanket travel bans over the new Omicron coronavirus variant as governments and scientists try to determine how much protection current vaccines would offer against the strain.
The EU's drugs agency EMA has started evaluating an application for conditional marketing authorisation for US biotech firm Novavax’s COVID-19 vaccine, Nuvaxovid. If granted, this will be the fifth vaccine authorised in the European Union.